

UDOU

Course

10th edition

17–19 SEPTEMBER 2026

Mama Shelter Paris West

20 AVENUE DE LA PORTE DE LA PLAINE,
75015, PARIS
FRANCE

Organized by



&



NewMed
PUBLISHING

STEERING COMMITTEE



PR MORGAN ROUPRÊT

*Academic Professor of Urology;
Hôpital Pitié-Salpêtrière
AP-HP Sorbonne University
Paris, France*



PR ALEXANDRE DE LA TAILLE

*Chair, Urology Dept; CHU Mondor.
Head, INSERM Research Team on
Translational Research in
Oncogenesis;
Paris, France*

SCIENTIFIC COMMITTEE



PR LAURENCE ALBIGES

*Chair of Medical
Oncology Department
Gustave Roussy,
Villejuif, France*



PR BERTRAND TOMBAL

*Chair, Division of Urology and
Associate Professor of Physiology;
Univ. Catholique de Louvain (UCL),
Brussels, Belgium*



DR ENRIQUE GRANDE

*Head of Medical Oncology Service,
MD Anderson Cancer Center,
Madrid, Spain*



DR ALBERTO BOSSI

*AMETHYST Radiotherapy,
Paris, France*



DR PAUL SARGOS

*Radiation Oncologist,
Institut Bergonié,
Bordeaux, France*



DR GUILHEM ROUBAUD

*Medical Oncologist,
Institut Bergonié,
Bordeaux, France*

FACULTY



DR RONAN FLIPPOT

MEDICAL ONCOLOGIST,
GUSTAVE ROUSSY, VILLEJUIF, FRANCE



DR CAROLE HELISSEY

MEDICAL ONCOLOGIST & HEAD OF THE
ONCOLOGY DEPARTMENT
HÔPITAL D'INSTRUCTION DES ARMÉES
BÉGIN, SAINT-MANDÉ, FRANCE



PR GAUTHIER MARCQ

ASSOCIATE PROFESSOR OF UROLOGY
CHU LILLE, UNIVERSITY OF LILLE, FRANCE



PR CHIARA MERCINELLI

MEDICAL ONCOLOGIST,
IRCCS SAN RAFFAELE HOSPITAL & VITA-SALUTE
SAN RAFFAELE UNIVERSITY, MILAN, ITALY



DR ROSSELLA NICOLETTI

UROLOGIST, CAREGGI UNIVERSITY
HOSPITAL & UNIVERSITY OF
FLORENCE
FLORENCE, ITALY



PR JONATHAN OLIVIER

PROFESSOR OF UROLOGY
CHU LILLE & UNIVERSITY OF LILLE, FRANCE



DR FRÉDÉRIC PANTHIER

ACADEMIC UROLOGIST,
TENON HOSPITAL, AP-HP, SORBONNE
UNIVERSITY, PARIS, FRANCE



DR MARIO TERLIZZI

RADIATION ONCOLOGIST,
GUSTAVE ROUSSY, VILLEJUIF, FRANCE



**DR CONSTANCE
THIBAUT**



DR LÉA TURPIN

HEAD OF NUCLEAR MEDICINE
DEPARTMENT
HÔPITAL FOCH, SURESNES, FRANCE

PROGRAM

17-19 **SEPTEMBER**
2026

DAY 1

THURSDAY, SEPTEMBER 17, 2026

1:00 PM

Introduction of UDOU Course 2026

1:30 PM

Artificial Intelligence for publications and medical research

Dr E. Floch

2:00 – 6:00 PM – PROSTATE CANCER MODULE

2:00 – 4:00 PM

Chair Dr M. Terlizzi / Dr G. Roubaud

Metastatic Hormone Sensitive Prostate Cancer

Rationale and data for triplet therapy (ADT + docetaxel + ARPI), ongoing trials and subgroup analyses.

Pr B. Tombal

Bone-targeted agents, cardiovascular risk assessment, exercise and rehabilitation interventions.

ADT alone vs combination strategies: docetaxel + ADT, AR-axis inhibitors (enzalutamide, abiraterone, apalutamide, darolutamide) + ADT – key trials (CHAARTED, STAMPEDE, LATITUDE, ARCHES, TITAN, ENZAMET).

Role of local therapy: radical prostatectomy and local radiotherapy in de novo metastatic disease (STAMPEDE RT data) and Stereotactic body radiotherapy (SBRT) for oligometastatic disease: evidence, patient selection, endpoints.

Pr B. Tombal

4:00 – 4:30 PM

Networking and exhibition visit

4:30 – 5:00 PM

FLASH SYMPO 1 – ASTELLAS

Dr M. Terlizzi



From high-risk BCR to mHSPC: a history of therapeutic intensification

5:00 – 6:30 PM

Chair Dr C. Mercinelli / Dr R. Nicoletti

Castration Resistant Prostate Cancer

- Recommended molecular tests (tumor NGS panels, germline BRCA testing, MMR/MSI testing) and timing of sampling (biopsy vs ctDNA).
- How do i include genomic alterations (BRCA1/2, ATM, mismatch repair deficiency, PI3K/AKT, PTEN) in my therapeutic decision?
- PARP inhibitors (olaparib, rucaparib): indications for BRCA/HRR alterations, key trials, resistance mechanisms and toxicities. / PI3K/AKT/mTOR inhibitors and targeted strategies for PTEN loss.
- PSMA radioligand therapy (177Lu-PSMA-617): major results, selection criteria and toxicities.

Dr G. Roubaud

Dr G. Roubaud

Dr G. Roubaud

Dr G. Roubaud

6:30 – 7:15 PM

**OPTIONAL WORKSHOP – HANDS ON TRAINING by COLOPLAST
THULEP in Bladder Cancer and BPH – Register at the front desk**



8:00 PM Dinner mama shelter rooftop restaurant

PROGRAM
17-19 **SEPTEMBER**
2026

DAY 2

FRIDAY, SEPTEMBER 18, 2026

8:30 AM - 12:30 PM - BLADDER CANCER MODULE

8:30 – 10:00 AM

Non-Muscle Invasive Bladder Cancer

Chair Pr M. Roupret

Starting point Bladder Cancer clinical cases discussion with all Faculty

- Urinary markers in bladder cancer: how can we implement current guidelines?
- Systemic Immunotherapy for high risk patient: where do we stand ?
- NMIBC BCG unresponsive: novel intra vesical therapeutic approaches

Dr G. Marcq

Pr M. Roupret

Dr G. Marcq

10:00 – 10:15 AM

Networking and exhibition visit

10:15 – 12:30 PM

Muscle Invasive Bladder Cancer

Chair Dr C. Thibault

Starting point Bladder Cancer clinical cases discussion with all Faculty

- Bladder imaging, detection of lymph node or distant metastasis with CT, MRI and PET/C
- Immunotherapy in combination with radical cystectomy: a game changer?
- Bladder-sparing strategies in MIBC

Dr E. Grande

Dr E. Grande

Dr P. Sargos

Metastatic Bladder Cancer

Dr E. Grande

- Update on the systemic management of metastatic bladder cancer

12:30 – 1:00 PM

FLASH SYMPO 2 – MSD

Dr C. Helissey & Dr G. Marcq

Perioperative management of bladder tumors



1:00 PM – 2:00 PM

LUNCH AT THE EXHIBITION HALLS

FRIDAY, SEPTEMBER 18, 2026

2:00 PM - 6:45 PM
RENAL CANCER AND UPPER TRACT MODULE

2:00 – 4:00 PM

Upper Tract Urothelial Cancer ——— **Chair Dr F. Panthier**

- Role for systemic therapy in locally advanced and metastatic UTUC
- UTUC & bladder cancer: disparate twins

Dr E. Grande

Pr M. Roupret

Localized renal cell carcinoma

- Organ sparing surgery: role of reconstructive 3D model
- What is new in adjuvant for RCC: Selection? Combination?

Dr F. Panthier

Pr L. Albiges

4:00 – 4:30 PM

Networking and exhibition visit

4:30 – 6:00 PM

RCC ——— **Chair Dr R. Flippot**

Role of radiotherapy in RCC

Dr P. Sargos

Starting point RCC clinical cases discussion

Advanced renal cell carcinoma

- How to choose combination for 1st line treatment of metastatic RCC?
- How to treat beyond first line?

Pr L. Albiges

Pr L. Albiges

8:00 PM

UDOU CLOSING DINNER

PROGRAM
17-19 **SEPTEMBER**
2026

DAY 3

SATURDAY, SEPTEMBER 19, 2026

8:00 AM - 12:30 PM - PROSTATE CANCER MODULE

8:00 – 10:00 AM

Localized and locally advanced Prostate Cancer ——— Chair Pr A .de la Taille & Pr M. Roupret

Starting point PCa clinical cases discussion with all faculty

Lecture of the French Association of Urology

- | | |
|---|--------------------|
| • Systematic and targeted biopsies or targeted only ? | Pr J. Olivier |
| • Focal therapies: which one and for who ? | Pr J. Olivier |
| • Which staging for advanced prostate cancer | Dr L. Turpin |
| • Can we avoid lymph node dissection in case of negative PET PSMA | Pr A. de la Taille |
| • Robotic Surgery for prostate cancer: which robot do I use | Pr J. Olivier |

10:00 – 10:30 AM

Networking and exhibition visit

10:30 – 12:30 AM

Chair Pr A .de la Taille & Pr M. Roupret

- | | |
|---|------------|
| • Brachytherapy: for who? | Dr A.Bossi |
| • Radiation therapy for localized and locally advanced prostate cancer with which hormonal therapy? | Dr A.Bossi |
-

12:30 AM

Light Lunch and conclusion